GOVX Q3'26 Earnings: EPS estimate is (1.09) USD

GeoVax Labs (GOVX) will report Q3'26 earnings on November 5. Analysts expect $0 revenue and a loss of $1.09 per share. The company plans to disclose results at 7:00 AM ET.

Original reporting
Published Nov 4, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GOVX Q3'26 Earnings: EPS estimate is (1.09) USD — source image
Decision brief

The 30-second read

$GOVXBearishLow
01

Why it matters

The negative EPS estimate suggests operational challenges, but any unexpected trial success could quickly reverse sentiment.

02

Market read

Earnings preview for a micro‑cap biotech; limited broader market impact unless trial news emerges.

03

What to watch

Potential upcoming clinical trial data or partnership announcements not mentioned could offset earnings weakness.

Relevance 4/10Novelty 3/10Timing: pre‑market on November 5

Background

GeoVax Labs is a clinical‑stage biotech focused on vaccine development; its earnings are closely watched for trial progress.

Company-level read

Ticker impact

$GOVXBearishHigh confidence
Context

GovX (GeoVax Labs) will report Q3'26 earnings on Nov 5 with an estimated EPS of -1.09 USD and zero revenue.

Expected impact

downward pressure as market prices in the negative EPS forecast

Evidence & confidence

The consensus estimate shows a loss per share and no revenue, which typically triggers a sell-off.

Market effects

Biotech sector may see modest weakness as a small‑cap loss adds to broader earnings disappointment.

US biotech investors likely adjust positions ahead of the release.

Limited; impact confined to niche biotech investors.

Counterpoint

If the market overreacts to the negative estimate, a short‑term bounce could occur on any positive trial news.

Key entities

  • GeoVax Labs, Inc.

    Biotech firm developing vaccine platforms.

Related articles

$GOVXLow

EQS-News: GeoVax, Inc.: GeoVax Confirms Bundibugyo Ebola Vaccine Construct

GeoVax Labs, Inc. (GOVX) announced the development of a vaccine construct targeting Bundibugyo virus (BDBV) using its proprietary MVA-based rapid-cloning technology. The construct is a milestone toward a potential BDBV vaccine candidate, building on the company's existing filovirus vaccine portfolio. GeoVax's GEO-MVA vaccine for mpox and smallpox remains its primary focus, with a Phase 3 trial planned for late 2026. The World Health Organization (WHO) has called for accelerated development of BD

$GOVXMed

EQS-News: GeoVax, Inc.: GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study

GeoVax Labs (Nasdaq: GOVX) said it completed manufacturing, regulatory, clinical and preclinical milestones for its GEO-MVA pivotal Phase 3 immune-bridging study, scheduled to start in Q4 2026. The company expects a 500-participant trial and to report results in mid-2027, comparing GEO-MVA immune responses with licensed MVA-BN (Imvanex).

$GOVXMed

GeoVax Reports Second Quarter 2026 Financial Results

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_993355.htm EXHIBIT 99.1 ex_993355.htm Exhibit 99.1 GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update Company Advances GEO-MVA Toward Planned Pivotal Immunobridging Study Under Expedited Regulatory Pathway ATLANTA, GA, July 27, 2026 – G

$CISSMedAI 8/10

C3is (CISS) Q3 2026 Earnings Call Transcript

C3is (CISS) reported Q3 2026 earnings, with voyage revenues up 249% YoY to $16.7M and nine-month revenues up 116% to $52.4M. Adjusted net income increased 1,300% YoY to $13.2M. Cash balance rose 335% to $64.9M. The company expanded its fleet and secured time charters for bulk carriers. Management highlighted strong market demand for iron ore, coal, and grain, driving shipping rates.